Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
The FDA approves Regeneron's Livsayis as the first siRNA therapy for adults with generalized myasthenia gravis, requiring four annual doses.
Last updated: 2026-11-19 20:53:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $927.70, with a market capitalization of $99.08B and a P/E ratio of 20.57. Over the past 52 weeks, its price has ranged from $591.52 to $991.73. This page covers its latest market performance, valuation, price trends and company information.
$99.08B | |
$947.68 | |
$956.49 | |
$921.79 | |
$945.53 | |
452.06K | |
805.52K | |
20.57 | |
$991.73 | |
$591.52 | |
0.39% | |
2026-09-30 |
Regeneron Pharmaceuticals Inc. (REGN) is currently trading at $927.70 as of 2026-11-19 20:36:46, down 1.99% ($18.82) from the previous close of $945.53
During today's regular trading session, REGN has traded between $921.79 and $956.49, with a trading volume of 452.06K shares. The current price is near the lower end of today's range.
Over the past seven days, Regeneron Pharmaceuticals Inc. (REGN) moved from $916.06 to $927.70, representing a gain of 1.27% ($11.64).
The stock traded between $898.29 and $981.55 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 923.90 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.0%
REGN is currently trading at $927.70, placing it 84.0% of the way from its 52-week low of $591.52 to its 52-week high of $991.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15,410 |
| CEO | Leonard S. Schleifer |
| Founded | 1988 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Regeneron Pharmaceuticals Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 20, 2026 |
| Payment Date | Dec 3, 2026 |
| Dividend Per Share | $0.94 |
Latest news related to Regeneron Pharmaceuticals Inc. and REGN stock.
The FDA approves Regeneron's Livsayis as the first siRNA therapy for adults with generalized myasthenia gravis, requiring four annual doses.
Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating
The FDA has approved Livsayis™ (cemdisiran), developed by Regeneron Pharmaceuticals, as the first and only FDA-approved siRNA therapy for generalized myasthenia gravis (gMG) in anti-AChR antibody-positive patients. The subcutaneous treatment administered four times yearly targets complement component factor 5 (C5) to reduce immune-mediated damage at the neuromuscular junction, expanding therapeutic options for this chronic autoimmune neuromuscular disease.
Eligible investors can buy real shares of Regeneron Pharmaceuticals Inc. (REGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to REGN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between REGN shares and USD.
REGN Shares to USD
1.00 REGN shares = 927.698 USD
Calculations are estimates based on the latest available price and are for reference only.